Navigation Links
New insights into salt transport in the kidney
Date:8/23/2012

Sodium chloride, better known as salt, is vital for the organism, and the kidneys play a crucial role in the regulation of sodium balance. However, the underlying mechanisms of sodium balance are not yet completely understood. Researchers of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch, Charit Universittsmedizin Berlin and the University of Kiel have now deciphered the function of a gene in the kidney and have thus gained new insights into this complex regulation process (PNAS Early Edition, doi/10.1073/pnas.1203834109)*.

In humans, the kidneys filter around 1700 liters of blood every day, of which 180 liters are collected as primary urine and ultimately one to two liters of urine are excreted. The kidneys thus wash toxic waste products out of the body, but retain some useful substances and reintroduce them into the body, thus simultaneously regulating the salt and water balance.

Molecular velcro

In the study just published by Dr. Tilman Breiderhoff, Prof. Thomas Willnow (both MDC), as well as Dr. Nina Himmerkus and Prof. Markus Bleich (both of the University of Kiel) and Dr. Dominik Mller (Charit) the focus is on the claudin-10 gene, which is expressed in a specific segment of the kidney, in Henle's loop. In the thick ascending limb of this loop, , a large part of the filtered sodium chloride, as well as calcium and magnesium are reabsorbed. The gene product under investigation, the claudin 10 protein, belongs to a family of proteins that connect the epithelial cells which cover the inner and outer surfaces of the body and stick them together like velcro. Claudins, however, also form pores, through which ions and substances are transported between the cells.

"If these transport processes are disturbed, this can lead to serious loss of function of the kidneys," Dr. Breiderhoff explained. As example he cited various human hereditary diseases in which either absorption of table salt (Bartter syndrome) or of calcium and magnesium (familial hypomagnesemia with hypercalciuria and nephrocalcinosis FHHNC) is disturbed. The second disease is characterized by a lack of magnesium in the blood and an excess of calcium in the urine, which leads to calcification of the kidneys. It is caused by mutations in one of two genes (claudin 16 or claudin 19), which also belong to the gene family of the claudins.

The researchers have now demonstrated in mice that the claudin-10 gene is involved in the reabsorption of salt in the kidney. If the gene in the kidney is deactivated, the reabsorption of sodium is impaired, but the reabsorption of calcium and magnesium is increased. The consequence is that the mice have elevated magnesium levels in the blood, and excess calcium is deposited in the kidney. Simultaneously, the urine volume is increased because the kidneys of the mice cannot reabsorb enough water, a sign that the recovery of salt is disturbed.


'/>"/>
Contact: bachtler@mdc-berlin.de
bachtler@mdc-berlin.de
49-309-406-3896
Helmholtz Association of German Research Centres
Source:Eurekalert  

Related medicine news :

1. Researchers fish-eye view could offer insights for human vision
2. Feces fossils lend new insights into connection between Native-Americans, diabetes
3. Scientists at the Mainz University Medical Center gain new insights into Taspase1 function
4. Better treatment for brain cancer revealed by new molecular insights
5. Aggregating instead of stabilizing: New insights into the mechanisms of heart disease
6. Understanding and promoting mental health - Insights from psychological science
7. New insights into when beach sand may become unsafe for digging and other contact
8. From a Failed Vaccine, New Insights Into Fighting HIV
9. K9 CarFence™ Launches as Newest Innovation in Pet Transportation
10. Men Have a Greater Lifetime Risk for Kidney Failure: Study
11. Drinking Iced Tea Raises Kidney Stone Risk: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New insights into salt transport in the kidney
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... compare student test score performance for the 2015-16 school year across Wisconsin’s public ... programs. Though it highlights important patterns in student test score performance, the report’s ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
Breaking Medicine Technology: